Matthew M Y Lee
Overview
Explore the profile of Matthew M Y Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomasoni D, Codina P, Lee M, Aimo A
Eur J Heart Fail
. 2025 Feb;
27(2):185-189.
PMID: 40000416
No abstract available.
2.
Lee M, Ghouri N, Misra A, Kang Y, Rutter M, Gerstein H, et al.
Diabetes Care
. 2025 Feb;
48(3):489-493.
PMID: 39977628
Background: Cardiovascular outcome trials (CVOTs) suggest glucagon-like peptide 1 receptor agonists (GLP-1RAs) provide greater cardiovascular (CV) benefits in Asian compared with White individuals. Purpose: Compare CV efficacy of GLP-1RAs between...
3.
Sattar N, Lee M
Lancet Diabetes Endocrinol
. 2025 Jan;
PMID: 39870097
The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions...
4.
Osmanska J, Docherty K, Berry C, Jhund P, Mangion K, Mark P, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39792133
Aims: A cardiovascular magnetic resonance (CMR) approach to non-invasively estimate left ventricular (LV) filling pressure was recently developed and shown to correlate with invasively measured pulmonary capillary wedge pressure (PCWP)....
5.
Codina P, Lee M, Tomasoni D, Aimo A
Eur J Heart Fail
. 2024 Dec;
26(12):2477-2481.
PMID: 39739985
No abstract available.
6.
Carberry J, Petrie M, Lee M, Stanley B, Brooksbank K, Campbell R, et al.
Eur J Heart Fail
. 2024 Dec;
PMID: 39675781
Aims: Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are considered to be at risk of progressive adverse cardiac remodelling which can lead...
7.
Badve S, Bilal A, Lee M, Sattar N, Gerstein H, Ruff C, et al.
Lancet Diabetes Endocrinol
. 2024 Nov;
13(1):15-28.
PMID: 39608381
Background: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains...
8.
Osmanska J, Petrie M, Docherty K, Lee M, McMurray J, Campbell R
Eur Heart J Cardiovasc Pharmacother
. 2024 Nov;
11(1):94-104.
PMID: 39520561
Background And Aim: Intravenous loop diuretics are the primary treatment for congestion in patients with decompensated heart failure (HF). Furosemide is the most commonly used loop diuretic and is licensed...
9.
Lee M, Codina P, Tomasoni D, Aimo A
Eur J Heart Fail
. 2024 Oct;
26(10):2049-2054.
PMID: 39402931
No abstract available.
10.
Maron M, Masri A, Nassif M, Barriales-Villa R, Abraham T, Arad M, et al.
J Am Coll Cardiol
. 2024 Oct;
84(19):1821-1831.
PMID: 39352339
Background: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has...